Core Viewpoint - The Chinese innovative drug sector is experiencing rapid growth, positioning itself as a global leader in drug development, with significant investments and collaborations from major pharmaceutical companies [2][8][30]. Group 1: Market Dynamics - The price of experimental monkeys has surged from 3,000 yuan to 100,000 yuan, indicating a high demand in the innovative drug sector [1]. - By 2025, China is projected to rank second globally in new drug clinical trials, with its pipeline accounting for 30% of the global total [2]. - In 2024, Chinese innovative drug companies completed 94 overseas licensing transactions, representing 44% of the national total, with over 100 transactions exceeding $100 billion in the first ten months of 2025 [6][30]. Group 2: Challenges in Traditional Pharmaceutical Sector - The generic drug sector is facing significant challenges, with a projected 5.5% decline in revenue for 2024 and over 30% of companies experiencing losses [5]. - Major pharmaceutical companies are increasingly collaborating with Chinese innovative drug firms to mitigate the risks associated with patent expirations, which could lead to a revenue gap exceeding $300 billion in the next five years [10][30]. Group 3: Advantages of Chinese Innovative Drugs - China offers a cost-effective and efficient environment for drug development, with clinical trial costs significantly lower than in the U.S. [20][21]. - The average time for clinical trial approvals in China has been reduced from 60 to 30 working days, and the average new drug application approval time has decreased to approximately 130 days [14]. - Chinese pharmaceutical companies are increasingly moving from "me-too" and "me-better" drugs to original innovations, with a notable increase in the number of innovative drug projects [27]. Group 4: Global Positioning and Future Outlook - Despite the rapid growth of Chinese innovative drugs, the overall market value of Chinese biotech companies remains significantly lower than their U.S. counterparts, capturing only 5% to 10% of global new drug revenues [30][31]. - Chinese companies are establishing commercial centers in global pharmaceutical hubs to enhance their commercialization capabilities, marking a shift towards becoming major players in the global market [37][38]. - The transition from biotech firms to large multinational pharmaceutical companies is seen as a critical step in the global battle for market share and innovation [38].

Group 1 - The core announcement is that the company, Heptares Therapeutics, exercised warrants under a licensing and collaboration agreement with Spruce Biosciences Inc. [1] - The company and its subsidiary, HBM Alpha Therapeutics, will hold approximately 3.8% of the total shares outstanding and about 3.1% of fully diluted shares of Spruce after exercising the warrants on January 19, 2026 [1] - The announcement includes a caution for shareholders and potential investors to act prudently, as there is no guarantee of successful development or eventual sales of any candidate products mentioned [1]

于2026年1月19日，本公司及HBMAT根据该协议行使认股权证。于行使认股权证后，本公司持有Spruce 发行在外股份总数的约3.8%及Spruce全面摊薄股份的约3.1%。 和铂医药-B(02142)发布公告，内容有关(其中包括)本公司孵化的创新型生物技术公司HBM Alpha Therapeutics(HBMAT)与Spruce Biosciences Inc.(Spruce)订立授权及合作协议(该协议)，以推进针对多种 疾病的新型促肾上腺皮质激素释放激素(CRH)靶向疗法。根据该协议，HBMAT及其联属人士获得少数 股权相关的认股权证以购买Spruce普通股股份(认股权证)。 ...

于2026年1月19日，本公司及HBMAT根据该协议行使认股权证。于行使认股权证后，本公司持有Spruce 发行在外股份总数的约3.8%及Spruce全面摊薄股份的约3.1%。 智通财经APP讯，和铂医药-B(02142)发布公告，内容有关(其中包括)本公司孵化的创新型生物技术公司 HBM Alpha Therapeutics(HBMAT)与Spruce Biosciences Inc.(Spruce)订立授权及合作协议(该协议)，以推 进针对多种疾病的新型促肾上腺皮质激素释放激素(CRH)靶向疗法。根据该协议，HBMAT及其联属人 士获得少数股权相关的认股权证以购买Spruce普通股股份(认股权证)。 ...

Core Viewpoint - HBM Alpha Therapeutics, a biotech company incubated by the company, has entered into a licensing and collaboration agreement with Spruce Biosciences to advance novel CRH-targeted therapies for various diseases [1] Group 1: Agreement Details - The agreement allows HBMAT and its affiliates to obtain warrants related to minority equity to purchase common stock of Spruce [1] - The company and HBMAT will exercise the warrants on January 19, 2026 [1] Group 2: Equity Holdings - Upon exercising the warrants, the company will hold approximately 3.8% of Spruce's outstanding shares and about 3.1% of Spruce's fully diluted shares [1]

Core Insights - Harbour BioMed has exercised its warrant to acquire common stock in Spruce Biosciences, holding approximately 3.8% of total outstanding shares and 3.1% of fully diluted shares of Spruce [1][3] Company Overview - Harbour BioMed is a global biopharmaceutical company focused on discovering and developing novel antibody therapeutics in immunology and oncology [4] - The company is enhancing its pipeline through internal R&D, strategic global collaborations, and selective acquisitions [4] Collaboration Details - The warrant was issued in connection with a license and collaboration agreement between HBM Alpha Therapeutics and Spruce, aimed at advancing the development of SPR202, a monoclonal antibody for various disorders [2] - This collaboration signifies a shift from a traditional licensor-licensee relationship to a strategic partnership, emphasizing a shared commitment to developing transformative therapies [3]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 和鉑醫藥控股有限公司 HBM Holdings Limited （於開曼群島註冊成立的有限公司） 1. 根據截至2025年9月30日Spruce發行在外股份總數及全面攤薄股份計算得出。 1 （股份代號：02142） 自願公告 根據與Spruce Biosciences Inc.訂立的授權及合作協議行使認股權證 本公告由和鉑醫藥控股有限公司（「本公司」，連同其附屬公司統稱「本集團」）自願 作出，以告知本公司股東及潛在投資者有關本集團的最新業務更新。 茲提述本公司日期為2025年2月26日的公告（「該公告」），內容有關（其中包括）本 公司孵化的創新型生物技術公司HBM Alpha Therapeutics（「HBMAT」）與Spruce Biosciences Inc.（「Spruce」）訂立授權及合作協議（「該協議」），以推進針對多種疾 病的新型促腎上腺皮質激素釋放激素(CRH)靶向療法。根據該協議，HB ...

| 表格序號 | 大股東/董事/最高行政人員名 作出披露的 買入 / 賣出或涉及的 每股的平均價 | | | | 持有權益的股份數目 佔已發行的 有關事件的日期 相 | | | --- | --- | --- | --- | --- | --- | --- | | | 股份數目 | 原因 | | | (請參閱上述 * 註 | 有投票權股 (日 / 月 / 年) 材 | | | | | | | 留 | 份百分比 | | and and and the many of the contraction of the CS20260116E00207 | GIC Private Limited | 1101(L) | 500.000(L) | HKD 14.5128 | 71.954.000(L) | 8.05(L)14/01/2026 | 增持后，GIC Private Limited最新持股数目为7195.4万股，持股比例由7.99%上升至8.05%。 | 股份代號: | 02142 | | --- | --- | | 上市法國名稱: | 01/05/2019 11:20:50 和鉑醫藥控股有限公司 - | | ...

Group 1 - GIC Private Limited increased its stake in Andlitz Pharmaceuticals (02142) by purchasing 500,000 shares at a price of HKD 14.5128 per share, totaling HKD 7.2564 million [1] - After the acquisition, GIC's total shareholding in Andlitz Pharmaceuticals reached 71.954 million shares, representing an ownership percentage of 8.05% [1]

智通财经APP获悉，香港联交所最新资料显示，1月14日，GIC Private Limited增持和铂医药(02142)50万 股，每股作价14.5128港元，总金额为725.64万港元。增持后最新持股数目为7195.4万股，最新持股比例 为8.05%。 ...